Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Ruihua Bai, Tianshun Zhang, Yongping Song, Qingxin Xia, Kangdong Liu, Zigang Dong, Qiushi Wang, Xiang Li, Keke Wang, Xiaoyu Chang, Ting Wang, Ann M. Bode, Joohyun Ryu, Wei-Ya Ma
Publikováno v:
Cancer Prevention Research. 12:837-848
Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinica
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Gregory J. Riely, Marc Ladanyi, Ryan Kim, Ken Suzawa, Matthew D. Hellmann, Helena A. Yu, Maria E. Arcila, Ahmet Zehir, Ai Ni, Bob T. Li, Michael F. Berger, Romel Somwar, Emmet Jordan, Mark G. Kris, David B. Solit
Publikováno v:
Clinical Cancer Research. 24:3108-3118
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics. 16:555-565
MET or hepatocyte growth factor (HGF) receptor pathway signaling mediates wound healing and hepatic regeneration, with pivotal roles in embryonic, neuronal, and muscle development. However, dysregulation of MET signaling mediates proliferation, apopt
Autor:
Randall J. Kimple, Johan Lantto, Zachary S. Morris, David M. Francis, Craig R. Hullett, Eric A. Armstrong, Chunrong Li, Paul M. Harari, Lauryn R. Werner, Adam D. Swick, Michael Kragh, Shyhmin Huang
Publikováno v:
Clinical Cancer Research. 22:633-643
Purpose: Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers. Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal anti
Autor:
Sumie Koike, Ryohei Katayama, Jeffrey A. Engelman, Kengo Takeuchi, Makoto Taiji, Alice T. Shaw, Justin F. Gainor, Luc Friboulet, Elizabeth L. Lockerman, Tahsin M. Khan, A. John Iafrate, Yasushi Okuno, Naoya Fujita
Publikováno v:
Clinical Cancer Research. 20:5686-5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non–small cell lung cancer (NSCLC). Several next-generation ALK-TKIs have entered the clinic and have shown promisin
Autor:
Daniel B. Costa, Susumu Kobayashi, Sohei Nakayama, Julian Carretero, Hiroyuki Yasuda, Alistair J. Tan, Ross A. Soo, Mihoko Yamamoto, Kenzo Soejima, Norihiro Yamaguchi, Danan Li, Kwok-Kin Wong, Robert S. Welner, Yuichiro Hayashi, Natasha J. Sng
Publikováno v:
Cancer Research. 74:5891-5902
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is avai
Autor:
Antonio García de Herreros, Manuel Domine, Silvia Menendez, Montserrat Arumi-Uria, Sandra Zazo, Lara Pijuan, Israel Cañadas, Oriol Arpí, Edurne Arriola, Sergi Mojal, Federico Rojo, Joan Albanell, Marta Salido, Ana Rovira, Álvaro Taus
Publikováno v:
Clinical Cancer Research. 20:938-950
Purpose: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte growth factor (HGF)/Met–mediated epithelial-to-mesenchymal transition (